| Criner, Gerard J |
VIGOR, NCT05583188: Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC |
|
|
| Terminated | 4 | 5 | US | Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Carboplatinum, Cipsplatin, Pemetrexed, Gemcitabine, Paclitaxel, Standard of care neoadjuvant therapy, Vinorelbine, Surgical Resection | Galvanize Therapeutics, Inc. | NSCLC | 02/24 | 03/24 | | |
| Recruiting | 4 | 1250 | US | Roflumilast, Daliresp, Azithromycin, Zithromax | Johns Hopkins University, Patient-Centered Outcomes Research Institute, University of Illinois at Chicago | Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis | 03/26 | 05/26 | | |
| Completed | 3 | 220 | Europe, US, RoW | Liposomal Cyclosporine A, L-CsA, Standard of Care, SoC | Zambon SpA, BREATH Therapeutics Inc. | Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction | 03/24 | 03/24 | | |
| Completed | 3 | 220 | Europe, US, RoW | Liposomal Cyclosporine A, L-CsA, standard of care, SoC | Zambon SpA, BREATH Therapeutics Inc. | Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction | 04/24 | 04/24 | | |
| Completed | 3 | 806 | Europe, Canada, US, RoW | Placebo, Mepolizumab | GlaxoSmithKline, PPD DEVELOPMENT, LP | Pulmonary Disease, Chronic Obstructive | 08/24 | 08/24 | | |
|
|
|
|
|
| Active, not recruiting | 3 | 689 | Europe, Canada, Japan, US, RoW | Benralizumab, Placebo | AstraZeneca | Chronic Obstructive Pulmonary Disease | 08/25 | 08/25 | | |
|
| Active, not recruiting | 3 | 202 | US | N-acetyl cysteine, NAC, Placebo | Weill Medical College of Cornell University, University of Virginia, University of Michigan, Pulmonary Fibrosis Foundation, University of Washington, National Heart, Lung, and Blood Institute (NHLBI), Three Lakes Foundation | Idiopathic Pulmonary Fibrosis | 02/26 | 02/26 | | |
| Recruiting | 2 | 340 | US | Hypothermia, targeted temperature management, Neuromuscular Blocking Agents, Paralytics, Standard of care, Usual temperature managementl | University of Maryland, Baltimore, US Department of Veterans Affairs Cooperative Studies Program, KAI Research, United States Department of Defense | Respiratory Distress Syndrome, Adult | 06/26 | 09/26 | | |
| Active, not recruiting | 2 | 48 | Europe, RoW | RXC007, Placebo | Redx Pharma Plc, Simbec-Orion Group | IPF, Fibrosis | 06/24 | 01/25 | | |
|
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) |
|
|
| Recruiting | 2 | 150 | Europe, Canada, US, RoW | GSK3915393, Placebo | GlaxoSmithKline | Idiopathic Pulmonary Fibrosis | 03/26 | 03/26 | | |
| Recruiting | 2 | 400 | US | Amlitelimab, BI 1015550, Placebo | Scleroderma Research Foundation, Inc., Sanofi, Boehringer Ingelheim | Interstitial Lung Disease Due to Systemic Disease, Scleroderma | 11/26 | 11/26 | | |
NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Terminated | 2 | 153 | Europe, Canada, Japan, US, RoW | HZN-825, Placebo | Amgen | Idiopathic Pulmonary Fibrosis | 07/24 | 01/25 | | |
|
| Recruiting | 2 | 30 | US | Dexpramipexole Dihydrochloride | Areteia Therapeutics | Chronic Obstructive Pulmonary Disease | 04/25 | 06/25 | | |
| Completed | 2 | 51 | US | Autoantibody Reductive Therapy, Treatment as Usual (TAU), Antibiotics and steroids | University of Alabama at Birmingham, National Heart, Lung, and Blood Institute (NHLBI), Brigham and Women's Hospital, Temple University, University of Pittsburgh | Idiopathic Pulmonary Fibrosis, Acute Fatal Form | 08/24 | 08/24 | | |
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 75 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 07/25 | | |
| Recruiting | 2 | 250 | US | Doxycycline, Placebo | Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI), University of California, Los Angeles, University of Iowa, University of Michigan | Emphysema, HIV | 02/27 | 02/27 | | |
NCT05571059: Oral Ifetroban in Patients with Idiopathic Pulmonary Fibrosis (IPF) |
|
|
| Recruiting | 2 | 128 | US | Ifetroban Sodium, ifetroban, Placebo | Cumberland Pharmaceuticals | Idiopathic Pulmonary Fibrosis | 01/26 | 01/26 | | |
NCT05195918: Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients |
|
|
| Recruiting | 1 | 50 | US | EGCG 300 mg + Nintedanib, epigallocatechin-3-gallate + Ofev, EGCG 300 mg + Pirfenidone, epigallocatechin-3-gallate + Esbriet, Placebo 2 capsules + Nintedanib or Pirfenidone, Placebo + Ofev or Esbriet, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone | Hal Chapman, University of Michigan, Cornell University, Massachusetts General Hospital, Temple University, University of Washington, University of Virginia | Idiopathic Pulmonary Fibrosis | 04/26 | 04/26 | | |
NCT01796392: Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study) |
|
|
| Completed | N/A | 190 | Europe, US, RoW | EBV, Optimal Medical Management | Pulmonx Corporation | Emphysema | 09/17 | 04/23 | | |
NCT05182294: Tolerance and Acute Effects of a New HFNT Nasal Cannula |
|
|
| Completed | N/A | 14 | US | AIRVO 2, the new asymmetric nasal cannula, Conventional asymmetric nasal cannula | Temple University, Fisher and Paykel Healthcare | COPD Exacerbation Acute | 12/22 | 01/23 | | |
RESCUE3, NCT03783884: A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning From Mechanical Ventilation |
|
|
| Terminated | N/A | 223 | Europe, US | Lungpacer Diaphragm Pacing Therapy, Lungpacer DPTS, AeroPace System | Lungpacer Medical Inc. | Ventilator Induced Diaphragm Dysfunction | 12/22 | 01/23 | | |
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema |
|
|
| Recruiting | N/A | 200 | Europe, US, RoW | AeriSeal System | Pulmonx Corporation | Emphysema, Pulmonary, Emphysema or COPD | 06/27 | 03/28 | | |
HFCWO, NCT04271969: Clinical Effectiveness Of High Frequency Chest Wall Oscillation () In A Bronchiectasis Population |
|
|
| Completed | N/A | 25 | US | SmartVest Airway Clearance System | Electromed, Inc., University of Alabama at Birmingham | Bronchiectasis | 12/23 | 12/23 | | |
NCT05204875: Functional Lung Imaging in Patients With Respiratory Compromise Undergoing Endobronchial Valve Placement |
|
|
| Recruiting | N/A | 10 | US | X-ray Velocimetry | Temple University, Respiratory Compromise Institute | Emphysema | 11/23 | 12/23 | | |
| Active, not recruiting | N/A | 210 | Europe, US | RejuvenAir System, Sham Control Procedure | CSA Medical, Inc. | Chronic Bronchitis | 05/25 | 09/26 | | |
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis |
|
|
| Active, not recruiting | N/A | 270 | Europe, US | RheOx Bronchial Rheoplasty, Sham Procedure | Gala Therapeutics, Inc. | Chronic Bronchitis | 05/24 | 10/25 | | |
NCT04543461: American Lung Association (ALA) Lung Health Cohort |
|
|
| Recruiting | N/A | 4000 | US | | Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, Stanford University | Lung Diseases | 09/26 | 09/26 | | |
| Active, not recruiting | N/A | 2981 | US | | University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI), COPD Foundation, Columbia University, Johns Hopkins University, National Jewish Health, Temple University, University of Alabama at Birmingham, University of California, Los Angeles, University of California, San Francisco, University of Illinois at Chicago, University of Iowa, University of Michigan, University of Utah, Wake Forest University | COPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema | 12/30 | 12/30 | | |
| Active, not recruiting | N/A | 464 | Europe, US | Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care | Nuvaira, Inc. | COPD | 10/24 | 09/28 | | |
| Recruiting | N/A | 150 | US | Spiration Valve System (SVS) | Olympus Corporation of the Americas | Emphysema | 04/25 | 04/28 | | |
NCT05119556: Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | N/A | 768 | US | Video Telehealth Pulmonary Rehabilitation | University of Alabama at Birmingham, National Heart, Lung, and Blood Institute (NHLBI) | Chronic Obstructive Pulmonary Disease | 06/26 | 08/27 | | |
NCT04165564: DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers |
|
|
| Active, not recruiting | N/A | 85 | US | Institutional standard of care, Biosamples of airway and blood | Boston University, Johnson & Johnson, American College of Radiology Imaging Network | Pulmonary Disease | 12/26 | 12/26 | | |
| Venkatesh, Bala |
| Completed | 2 | 155 | RoW | Fludrocortisone Acetate, Standard Therapy | The George Institute | Critically Ill, Septic Shock | 04/23 | 06/23 | | |
| Recruiting | 2 | 450 | RoW | Denosumab 60 MG/ML, Prolia, Xgeva, Zoledronic Acid 5Mg/Bag 100Ml Inj, Zometa, Reclast, Aclasta, Sodium Chloride 0.9% or 5% Dextrose Intravenous, Saline, Placebo, Sodium Chloride 0.9% Injection | Australian and New Zealand Intensive Care Research Centre, Department of Health | Critical Illness, Osteoporosis | 02/27 | 02/27 | | |
ACTRN12610000267055: A trial of Plasmalyte vs Bicarbonate based prime in patients undergoing cardiopulmonary bypass |
|
|
| Active, not recruiting | 1/2 | 30 | | | Princess Alexandra hospital | Acid base abnormalities, Inflammation | | | | |
| Nguyen, Phan Anh Tuan |
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema |
|
|
| Recruiting | N/A | 200 | Europe, US, RoW | AeriSeal System | Pulmonx Corporation | Emphysema, Pulmonary, Emphysema or COPD | 06/27 | 03/28 | | |
| Ma, Kevin C |
NCT05433961: Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI |
|
|
| Not yet recruiting | 1 | 100 | NA | MagniXene Hyperpolarized Xenon MRI | Xemed LLC, University of Pennsylvania | COPD | 06/28 | 06/28 | | |
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema |
|
|
| Recruiting | N/A | 200 | Europe, US, RoW | AeriSeal System | Pulmonx Corporation | Emphysema, Pulmonary, Emphysema or COPD | 06/27 | 03/28 | | |
| Felice, Christopher Di |
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema |
|
|
| Recruiting | N/A | 200 | Europe, US, RoW | AeriSeal System | Pulmonx Corporation | Emphysema, Pulmonary, Emphysema or COPD | 06/27 | 03/28 | | |
